Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

ABSTRACT:

Importance

Biosimilar competition has been associated with in lower prices and decreased US health care spending, but this has not consistently led to lower out-of-pocket (OOP) costs for commercially insured patients using these medications.

Objective

To investigate whether biosimilar competition was associated with lower OOP spending for Medicare patients who used biologics.

Design, setting, and participants

This cross-sectional study used an event study design. Participants were patients with Medicare Advantage coverage in a national commercial claims database (Optum's deidentified Clinformatics Data Mart Database) who used 1 of 7 clinician-administered biologics (filgrastim, infliximab, pegfilgrastim, epoetin alfa, bevacizumab, rituximab, and trastuzumab) from 2009

SUBMITTER: Riegler JS 

PROVIDER: S-EPMC12809370 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature